Get started
Author

Jake Micallef

Observed names: J Micallef, J. Micallef, J.V. Micallef, Jake MiCallef, Jake V. Micallef, Micallef, Jake
Institution: Volition (Belgium)
OpenAlex ID: A5112728298
A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae
2022 · Peter M. George, Anna Reed, et al. · Science Translational Medicine · 110
PDF
Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer
2015 · Monika Bauden, Dorian Pamart, et al. · Clinical Epigenetics · 110
PDF
Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer
2017 · Jean-François Rahier, Anne Druez, et al. · Clinical Epigenetics · 86
PDF
Novel serum nucleosomics biomarkers for the detection of colorectal cancer.
2014 · Stefan Holdenrieder, Yoganiranjana Dharuman, et al. · PubMed · 39
Circulating cell-free nucleosomes as biomarkers for early detection of colorectal cancer
2017 · Louise Rasmussen, For the Danish Collaborative Group on Early Detection of Colorectal Cancer, et al. · Oncotarget · 36
PDF
Serological biomarkers in triage of FIT-positive subjects?
2017 · Hans J. Nielsen, Ib Jarle Christensen, et al. · Scandinavian Journal of Gastroenterology · 13
PDF
The Open University's First One-Day Symposium on Treatment-Emergent Neuroendocrine Prostate Cancer
2020 · Rebecca L Mather, Henry Andrews, et al. · Future Oncology · 11
PDF
Pre-analytical variables of circulating cell-free nucleosomes containing 5-methylcytosine DNA or histone modification H3K9Me3
2016 · Louise Rasmussen, Marielle Herzog, et al. · Scandinavian Journal of Clinical and Laboratory Investigation · 9
Circulating nucleosomes in hematological malignancy.
2020 · Jason Terrell, Eleonore Josseaux, et al. · Journal of Clinical Oncology · 4
Validation of Nu.Q™ colorectal cancer screening triage test to identify FIT positive individuals at low risk of screen relevant neoplasia
2017 · Marielle Herzog, Mark Eccleston, et al. · Annals of Oncology · 4
PDF
HTA151 The NICE Cost Comparison Pathway - How Much Evidence Is Required to Meet the Criteria?
2022 · A Thiam, K Noon, et al. · Value in Health · 2
PDF
MSR63 When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning
2022 · J Micallef, HE Harrington, et al. · Value in Health · 2
PDF
HTA141 Does NICE’s New Severity Modifier Capture the Value of Treatments for Long-Term Progressive Diseases? A Retrospective Analysis of Past Appraisals in Multiple Sclerosis
2022 · J Morgan, A Abdullah, et al. · Value in Health · 1
PDF
A novel epigenetic immunoassay approach to profiling circulating nucleosomes for CRC detection
2016 · M. Herzog, M.E. Eccleston, et al. · Annals of Oncology · 1
290eTiP Epigenetic nucleosomes in plasma for pulmonary nodule differentiation
2025 · P-H. Chen, T-H. Young, et al. · Annals of Oncology
PDF
282P: Early detection of stage I/II NSCLC by immunoassay of crosslinked plasma cell fee nucleosomes
2025 · J. Micallef, D. Pamart, et al. · Journal of Thoracic Oncology
PDF
179P Immunoprecipitation of tumor-associated ctDNA fragments for novel lung cancer liquid biopsy
2024 · J. Micallef, D. Pamart, et al. · ESMO Open
HTA7 Exploring the Predictive Accuracy of Treatment Waning Methods: An Analysis of Pembrolizumab across Six Oncology Indications
2023 · H. Harrington, A.V. Vasilyeva, et al. · Value in Health
PDF
HTA327 Acceptance of Real-World Evidence As Comparative Efficacy in Lieu of Trial Evidence: A Review of Past NICE Appraisals in Oncology
2023 · J. Morgan, L. Evans, et al. · Value in Health
205P A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer
2023 · D. Pamart, J-V. Turatsinze, et al. · Annals of Oncology
PDF
133MO Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma
2023 · P-H. Chen, T-M. Tsai, et al. · Annals of Oncology
PDF
HTA30 The NICE Vs SMC Cost Comparison Pathways – How Similar Are They?
2023 · H. Freeman, H. Morris, et al. · Value in Health
PDF
HTA26 Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC As a Case Study
2023 · H. Harrington, S. Madueke, et al. · Value in Health
PDF
MSR34 Forecasting the Long-Term Treatment Effect Duration of Immuno-Oncology Therapies: An Analysis of the Predictive Accuracy of Treatment Waning Methods Applied to Pembrolizumab in Non-Small Cell Lung Cancer
2022 · H Harrington, S Madueke, et al. · Value in Health
PDF
POSA266 Capturing the Value of Potentially Curative Oncology Therapies: Lessons from the Use and Acceptance of Cure Modelling Assumptions in NICE Technology Appraisals
2022 · J Micallef, A Satija, et al. · Value in Health
Works count: 42
Citation count: 428
H-index: 8
I10-index: 7
Year
Topic
Type